In a previous article, I noted that LinkedIn is barely used in Japan, and English-language announcements are usually ignored by the very people you want to reach. If you are serious about building a presence in Japan, you cannot rely on global channels alone. You need to invest in Japan-specific PR platforms that actually get seen by the right audiences.
Based on my experience supporting multiple European and North American pharma companies entering Japan, three platforms stand out: PR Times, Nikkan Yakugyo (日刊薬業), and Link-J. Each serves a different purpose, and together they provide a strong foundation for building visibility and credibility.
1. PR Times – The Ubiquitous Gateway to Visibility
I’ve used PR Times many times — and the results speak for themselves. If you Google almost any company or product name in Japan, a PR Times press release will be one of the top hits. That kind of SEO dominance is unique.
PR Times also conducts editorial review of every submission, which gives the platform credibility compared to overseas press wires that simply post whatever is paid for. This credibility rubs off on you — a critical factor in Japan where trust is everything.
Cost: about ¥33,000 (≈$220) per release, or subscription plans starting around ¥88,000/month for unlimited releases.
For a biotech announcing a funding round or a CDMO showcasing its entry into the Japanese market, PR Times is simply the most effective way to gain instant visibility and long-term discoverability.
2. Nikkan Yakugyo (日刊薬業) – The Trusted Voice of Pharma
When it comes to pharma news, everyone in Japan reads Nikkan Yakugyo. In my conversations with seasoned pharma experts, they always describe Nikkan Yakugyo and Jiho (its publisher) as the most trusted source in the industry.
Unlike PR Times, you can’t just buy space. Coverage is editorial, which means if your news is picked up, it has real weight. Being mentioned in Nikkan Yakugyo tells the market that your story matters to insiders — and Japanese executives, regulators, and investors will notice.
Cost: subscriptions for readers start at around ¥120,000/year per license, with corporate plans often higher. Advertising or advertorial placements are possible but priced at premium industry rates.
For a CDMO or biotech, this is less about routine announcements and more about achieving recognition when something truly significant happens — like a strategic partnership or major funding milestone.
3. Link-J – The Network Everyone Talks About
Talk to anyone in biotech in Japan and the name Link-J always comes up. It’s not a traditional media outlet but rather a life science innovation network that connects startups, pharma, investors, and academia.
What makes it valuable is its dual role:
- PR channel: members can post press releases and announcements directly on the Link-J site.
- Networking platform: events, seminars, and partnering sessions put you face-to-face with the community.
Cost: membership starts at around ¥150,000/year for startups (enrollment + annual fee), with higher tiers for larger companies.
For foreign biotech or CDMOs, Link-J membership signals commitment to Japan. It puts your updates in front of the most engaged biotech community, and it gives you opportunities to co-host events or get introduced to potential investors and partners.
Final Thoughts
These three platforms cover different layers of Japan’s PR ecosystem:
- PR Times → Broad exposure and SEO impact (affordable, high ROI).
- Nikkan Yakugyo → Deep credibility among pharma insiders (premium, editorially controlled).
- Link-J → Community visibility and networking in biotech (membership-based).
From my experience, a serious market entry strategy should combine all three:
- Use PR Times for immediate visibility.
- Seek Nikkan Yakugyo coverage when you have meaningful news.
- Invest in Link-J to embed yourself in the life science ecosystem.
If you are preparing to enter Japan, don’t just translate your English press releases — choose the platforms that Japan’s pharma and biotech leaders actually read and trust. That’s how you build real presence here.